The effects of neoadjuvant hormonal therapy on the course of PSA and testosterone in patients with low and intermediate-risk prostate carcinoma (NEO-ONE); A randomized controlled trial

Trial Profile

The effects of neoadjuvant hormonal therapy on the course of PSA and testosterone in patients with low and intermediate-risk prostate carcinoma (NEO-ONE); A randomized controlled trial

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Mar 2013

At a glance

  • Drugs Bicalutamide (Primary) ; Leuprorelin (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms NEO-ONE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top